Clinical trials: Angiotensin-Converting-Enzyme Inhibitor
Aortic Stenosis
Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis
Abundant evidence suggests that Angiotensin Converting Enzyme (ACE) inhibition potentially could reduce the hazardous effects of aortic stenosis and improve haemodynamics.
- Trial name
- NCT00252317
- Testing
- Captopril and Trandolapril, Captopril Test Dose and Trandolapril
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
COVID19, Influenza Vaccination
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares…
- Conditions
- COVID19, Influenza Vaccination, ACE Inhibitors, ARB
- Trial name
- NCT04367883
- Testing
- Antihistamine, Amantadine, ACEI
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Consorci Sanitari de Terrassa
Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day
Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown.
- Conditions
- Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day, Normal Blood Pressure, Serum Creatinine Below 120 Umol/l
- Trial name
- NCT01225445
- Testing
- Ramipril
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Hypertension
Precision Treatment With Angiotensin Converting Enzyme Inhibitor
Angiotensin converting enzyme inhibitors (ACEI) are the first-line treatment for high blood pressure and congestive heart failure, and have excellent effects in improving the prognosis of cardiovascular diseases.
- Trial name
- NCT05535595
- Testing
- genotyping and selection of renin-angiotensin system blocker, Perindopril
- Where
- South Korea
- Volunteers
- 77 people
- Sponsor
- Yonsei University
Diabetic Nephropathy Type 2, Microalbuminuria Due to Type 2 Diabetes Mellitus
Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination
The aim of our work is to compare the antiproteinuric efficacy of ACEI monotherapy, Selective MRA monotherapy and their combination in mildly hypertensive patients with type 2 diabetes mellitus and microalbuminuria
- Trial name
- NCT04143412
- Testing
- Tritace (Ramipril 10 mg)
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Beni-Suef University
Rheumatic Heart Disease, Mitral Stenosis
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients
Objective propose: to investigate the effect of Ramipril in suppressing ST2 (suppression of tumorigenicity 2) in the cardiac mitral valve in patients with Rheumatic Heart Disease.
- Conditions
- Rheumatic Heart Disease, Mitral Stenosis, Rheumatic Mitral Stenosis, Fibrosis; Heart
- Trial name
- NCT03991910
- Testing
- Ramipril 5Mg Oral Capsule
- Where
- Indonesia
- Volunteers
- 66 people
- Sponsor
- Universitas Indonesia
Intermittent Claudicants
Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
The investigators are conducting a randomised controlled trial to investigate the clinical and cost effectiveness of Ramipril which is an anti-hypertensive medication in patients with intermittent claudication.
- Trial name
- NCT01037530
- Testing
- Ramipril
- Where
- United Kingdom
- Volunteers
- 33 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Type 2 Diabetes
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
The purpose of the study is to investigate the effect of a blood pressure medication, Lisinopril, or similar drugs in that class, on the flow of blood to the kidneys.
- Trial name
- NCT01101269
- Testing
- ACEI or ARB, Lisinopril
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Chronic Hypertension
To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension
This is a two part study. Part 1 will determine determine if administration of TC-5214 has an effect on sitting blood pressure in patients with chronic hypertension.
- Trial name
- NCT01403922
- Testing
- TC-5214
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Hypertension, Blood Pressure, High
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension
The purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.
- Trial name
- NCT00355589
- Testing
- Ramipril and hydrochlorothiazide
- Where
- 60 sites in United States
- Sponsor
- Pfizer
Diabetes Mellitus, Diabetic Nephropathy
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
The purpose of this study is to evaluate the safety and tolerability of two dosing regimens of FG-3019 administered over 12 weeks in patients with diabetic nephropathy and proteinuria on background angiotensin converting enzyme…
- Trial name
- NCT00754143
- Testing
- FG-3019
- Where
- 18 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kyntra Bio
Hypotension, Anesthesia
Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs
Patient undergoing general anesthesia in elective surgery will be assigned to receive either methohexital or propofol general anesthesia.
- Trial name
- NCT02624050
- Testing
- Methohexital, Propofol
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Chronic Kidney Disease, Type 2 Diabetes
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
The purpose of this study is to evaluate the efficacy of ASP8232 in reducing Urinary Albumin to Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to…
- Trial name
- ALBUM (NCT02358096)
- Testing
- ASP8232
- Where
- 57 sites in Czechia, Denmark and 7 more
- Volunteers
- 125 people
- Sponsor
- Astellas Pharma Europe B.V.
Diabetes Mellitus, Type I, Diabetic Nephropathy
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
The primary aim is to evaluate the anti proteinuric effect of increasing doses of the ACE inhibitor, lisinopril: 20, 40 and 60 mg daily in type 1 diabetic patients with hypertension and diabetic nephropathy.
- Trial name
- NCT00118976
- Testing
- Lisinopril
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Steno Diabetes Center Copenhagen
Type 2 Diabetes
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4 inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of DPP-4…
- Trial name
- INDORSE (NCT02406443)
- Testing
- Sitaglitpin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Acute Coronary Syndrome
Secondary Prevention in Acute Coronary Syndromes: A CALIBER Study
All contemporary guidelines for secondary prevention in acute coronary syndromes recommend a combination of aspirin, beta-blockers, ACE-inhibitors and statins. Yet underutilisation of these drugs is common.
- Trial name
- NCT01162187
- Volunteers
- 400,000 people
- Sponsor
- University College, London
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure.
- Trial name
- NCT00412932
- Testing
- Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
- Where
- 29 sites in United States
- Volunteers
- 178 people
- Sponsor
- Daiichi Sankyo
C3 Glomerulopathy, Membranoproliferative Glomerulonephritis
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel treatment to block complement activation in the kidneys and thereby attenuate renal disease and stabilize or improve kidney function…
- Conditions
- C3 Glomerulopathy, Membranoproliferative Glomerulonephritis, Complement Abnormality, Dense Deposit Disease
- Trial name
- NCT04183101
- Testing
- Aliskiren, Enalapril
- Where
- 4 sites in Sweden
- Volunteers
- 30 people
- Sponsor
- Region Skane
Radiation Induced Fibrosis
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients…
- Trial name
- NCT05637216
- Testing
- Losartan 25 milligram capsule
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Shaw Cancer Center
Diabetes Mellitus, Type 2, Hypertension
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is…
- Trial name
- NCT00430040
- Testing
- Carvedilol Controlled Release (CR), lisinopril
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University at Buffalo